ESR1 and breast carcinoma: The additive pro-osteolytic effects of tumoral TGFβRII and ER signaling in bone-tropic ER+ cells also suggest a possible mechanism underpinning the clinical observation that bone-disseminated ER+ (vs. ER-) breast cancer cells appear more likely to progress to clinically evident osteolytic BMETs.